Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells
The claudin-low subtype is a recently identified rare molecular subtype of human breast cancer that expresses low levels of tight and adherens junction genes and shows high expression of epithelial-to-mesenchymal transition (EMT) genes. These tumors are enriched in gene expression signatures derived...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 109; no. 8; pp. 2778 - 2783 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
21.02.2012
National Acad Sciences |
Series | Breast Cancer Special Feature |
Subjects | |
Online Access | Get full text |
ISSN | 0027-8424 1091-6490 1091-6490 |
DOI | 10.1073/pnas.1018862108 |
Cover
Summary: | The claudin-low subtype is a recently identified rare molecular subtype of human breast cancer that expresses low levels of tight and adherens junction genes and shows high expression of epithelial-to-mesenchymal transition (EMT) genes. These tumors are enriched in gene expression signatures derived from human tumor-initiating cells (TICs) and human mammary stem cells. Through cross-species analysis, we discovered mouse mammary tumors that have similar gene expression characteristics as human claudin-low tumors and were also enriched for the human TIC signature. Such claudin-low tumors were similarly rare but came from a number of distinct mouse models, including the p53 null transplant model. Here we present a molecular characterization of 50 p53 null mammary tumors compared with other mouse models and human breast tumor subtypes. Similar to human tumors, the murine p53 null tumors fell into multiple molecular subtypes, including two basal-like, a luminal, a claudin-low, and a subtype unique to this model. The claudin-low tumors also showed high gene expression of EMT inducers, low expression of the miR-200 family, and low to absent expression of both claudin 3 and E-cadherin. These murine subtypes also contained distinct genomic DNA copy number changes, some of which are similarly altered in their cognate human subtype counterpart. Finally, limiting dilution transplantation revealed that p53 null claudin-low tumors are highly enriched for TICs compared with the more common adenocarcinomas arising in the same model, thus providing a unique preclinical mouse model to investigate the therapeutic response of TICs. |
---|---|
Bibliography: | SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 Author contributions: J.I.H., D.M., C.M.P., and J.M.R. designed research; J.I.H., W.Z., M.Z., J.U., G.M., D.E., J.K., S.B.G., D.D., M.A.T., S.G.H., and D.M. performed research; J.I.H., W.Z., M.Z., D.E., S.G.H., D.M., C.M.P., and J.M.R. contributed new reagents/analytic tools; J.I.H., W.Z., M.Z., J.U., J.K., S.B.G., M.A.T., S.G.H., D.M., C.M.P., and J.M.R. analyzed data; and J.I.H., W.Z., C.M.P., and J.M.R. wrote the paper. Edited by Kornelia Polyak, Dana-Farber Cancer Institute, Boston, MA, and accepted by the Editorial Board April 5, 2011 (received for review January 26, 2011) |
ISSN: | 0027-8424 1091-6490 1091-6490 |
DOI: | 10.1073/pnas.1018862108 |